| 000 | 01149 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250517221416.0 | ||
| 264 | 0 | _c20190103 | |
| 008 | 201901s 0 0 eng d | ||
| 022 | _a2212-3911 | ||
| 024 | 7 |
_a10.2174/1574886313666180601082412 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGarg, Aakriti | |
| 245 | 0 | 0 |
_aRisk and Benefit Profile of Dulaglutide in Established Therapeutic Indication. _h[electronic resource] |
| 260 |
_bCurrent drug safety _c2018 |
||
| 300 |
_a165-170 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Systematic Review | ||
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aGlucagon-Like Peptides _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadverse effects |
| 650 | 0 | 4 |
_aImmunoglobulin Fc Fragments _xadverse effects |
| 650 | 0 | 4 |
_aRecombinant Fusion Proteins _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aKumar, Anoop | |
| 773 | 0 |
_tCurrent drug safety _gvol. 13 _gno. 3 _gp. 165-170 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/1574886313666180601082412 _zAvailable from publisher's website |
| 999 |
_c28481571 _d28481571 |
||